Gilead Sciences (GILD)

Gilead Sciences boosted its full-year outlook after beating expectations. Gilead stock is hitting a 50-day line ceiling.

This week, from August 4th to August 10th, 2025, marks a busy period in the second-quarter earnings season, with hundreds of companies across various sectors scheduled to report their financial results. These earnings calls are crucial events for investors, analysts, and the broader market, as they provide insights into corporate

U.S. equities slipped midday Thursday as corporate earnings and fresh tariff announcements from President Donald Trump drove divergent moves in heavyweight names.

The Caviar Cruise strategy identifies high-quality stocks like Gilead Sciences (GILD) for long-term investment, focusing on strong growth, ROIC, low debt, and solid cash flow. GILD excels in profitability, valuation, and recession resilience.

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be reporting results this Thursday after market close. Here’s what investors should know.

Gilead Sciences (GILD) shows strong technical breakout potential with a high Technical Rating (10) and Setup Rating (8), indicating upward momentum and consolidation before a possible breakout.

The upgraded score means Gilead is now outperforming 96% of all stocks in terms of the most important stock-picking criteria.

pheton-holdings-dismisses-rumors-of-acquisition-by-gilead

Changes in a federal healthcare authority could negatively impact one of the company's important businesses.

The Supreme Court's Braidwood decision only concretized the power of the Department of Health and Human Services to decide what is necessary preventative care, rather than outright protecting pre-exposure prophylaxis, BMO said.

Visa, which will report third quarter results on Tuesday, July 29, is analyst Stephanie Link's final trade.

Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) jumped 3% in the afternoon session after its long-acting HIV prevention injection, lenacapavir, received a recommendation for approval from a key European regulatory committee. 

Gilead stock is flashing "buy" in bright green letters.

Gilead upgraded to Buy by Needham as Yeztugo gains physician favor, with sales forecast to reach $6.4 billion by 2035, exceeding prior estimates.

Needham has a $133 price target on the stock, representing an upside of about 17.5% to the stock’s closing price on Thursday.

Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues.